title: Complete response of recurrent cellular congenital mesoblastic nephroma to chemotherapy.
abstract: Congenital mesoblastic nephroma (CMN) is usually cured by surgery. The sensitivity of this tumor to chemotherapy is unknown. The recent description of a t(12;15)(p13;q25) chromosomal translocation in both cellular CMN and congenital infantile fibrosarcoma suggests that these entities have a common pathogenesis, and that cellular CMN might respond to chemotherapy like congenital infantile fibrosarcoma does. The authors describe three patients with recurrent cellular CMN who showed a complete response to chemotherapy. Based on these patients and a review of the literature, the authors suggest that chemotherapy be considered as a part of the therapy for recurrent or unresectable cellular CMN.
authors.affiliation: Department of Oncology Johns Hopkins University, Baltimore, Maryland, USA.
authors.forename: David M
authors.initials: DM
authors.lastname: Loeb
authors.forename: D Ashley
authors.initials: DA
authors.lastname: Hill
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Dome
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002675:Child, Preschool; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007680:Kidney Neoplasms / Q000151:congenital / Q000188:drug therapy* / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D018201:Nephroma, Mesoblastic / Q000151:congenital / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D012307:Risk Factors; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin